Quarterly Journal 46-1
In This Section
The AIPLA Quarterly Journal, a publication of the American Intellectual Property Law Association, is housed at the George Washington University Law School and is edited and managed by an Editorial Board of intellectual property experts and a staff of law students under the direction of the Editor-in-Chief, Professor Joan Schaffner.
![](https://www.aipla.org/images/default-source/news-publications/article-1-100.jpg?sfvrsn=b8dd69f3_3)
Bruce Alexander McDonald, Vladislav Ugryumov and Denis Kolesnikov
Compulsory Licensing of Pharmaceutical Patents in the Russian Federation Threatens Foreign and Domestic Drug Developers
Foreign and domestic developers of innovative drugs in the Russian Federation are bracing for the impact of possible amendments to antimonopoly and pharmaceutical laws proposed by the Russian Federal Antimonopoly Service (FAS) that would sharply limit patent protection for pharmaceutical products and medical devices. Among them are provisions that would institutionalize compulsory licensing in the pharmaceutical sector as an asserted means of lowering the cost of drugs and medical devices to Russian consumers.
![](https://www.aipla.org/images/default-source/news-publications/newspapers-100.jpg?sfvrsn=52ec597_3)
Lindsay Marks
Can Copyright Save the U.S. News Industry?
Today, newspapers across the world are struggling. The internet and online news brought about many problems for newspapers, including an unprofitable business model, an inattentive readership, and new competitors like news aggregators and social media sites. The unsustainability of newspapers is an issue fundamental to the state of our democracy.
![](https://www.aipla.org/images/default-source/news-publications/lightbulb-100.jpg?sfvrsn=a807e397_3)
Ashley Cade
Mistakes in Patent Law: Reforming the Reissue Statute in Light of Alice
This Note argues for an amendment to 35 U.S.C. § 251 — the Reissue Statute. Specifically, it proposes a change that would enable patent owners to cure defects in their patents for want of subject-matter eligibility. The Note explains that both
![](https://www.aipla.org/images/default-source/news-publications/marijuana-100.jpg?sfvrsn=e9ae3311_3)
Sarah Teitelman
The Stakes Have Never Been Higher: Why States Should Adopt a Model State Intent-to-Use Trademark Registration System to Facilitate the National Expansion of the Marijuana Industry
Marijuana legalization is one of the hot-button issues being debated in the United States. While a majority of citizens support marijuana legalization, the drug remains an illegal substance under the Controlled Substance Act (CSA). The United States Patent and Trademark Office has also made clear that until marijuana is rescheduled under the CSA, it will not register trademarks for marijuana goods and services because of the lawful use in commerce requirement. Accordingly, states have become the primary avenue for
This Note argues states that have legalized medical marijuana should adopt a Model State Intent-to-Use Registration System (Model ITU System) to facilitate the expansion of the marijuana industry. A Model ITU System would provide marijuana business quasi-national trademark rights through the use of intent-to-use trademark applications and secure protection for their brand signals before making substantial investments toward expansion. Additionally, a Model ITU System would promote the policy of trademarks serving as source identifiers for goods and services.
Upcoming Events
-
March In Rights and Compulsory Licenses
July 30, 2024 12:30 PM to 2:00 PM | Up to 90 Mins CLE
Join us as our speakers discuss march-in rights and compulsory licenses. Recent events like governmental agencies turning to march-in as a potential means to lower drug pricing or the pandemic have refueled the discussion on compulsory licenses here and in Europe. Our speakers will review the history of the Bayh Dole act as well as compulsory licenses in Europe and provide an overview of recent developments in both jurisdictions. Finally, the speakers touch on the implications and concerns for patent holders and future innovation in the biopharma space here and in Europe. -
AIPLA 2024 Annual Meeting
October 24 to 26, 2024
Join us as we bring IP professionals together to learn and connect. More information coming soon! The 2024 Annual meeting will take place at the Gaylord National Harbor Resort. Leadership Meetings on Wednesday, October 23. Programming scheduled October 24-26. -
2025 Leadership Forum
January 29 to 30, 2025
The Leadership Journey - From Survival (Subsistence) to Self-Fulfillment (Abundance). This invitation-only two-day program will address building strong leadership skills for all levels of experience. More details coming soon. -
2025 AIPLA Spring Meeting
May 13 to 15, 2025
Join us for this 2.5 day conference in Minneapolis, MN. Registration opens February 2025. More details coming soon!